Prospects for preventing infant invasive GBS disease through maternal vaccination (Q40317735)

19 September 2017

Prospects for preventing infant invasive GBS disease through maternal vaccination (English)

1 reference

19 September 2017

0 references

1

Shabir A Madhi

1 reference

19 September 2017

Ziyaad Dangor

2

1 reference

PubMed ID

28237500

19 September 2017

language of work or name

English

0 references

publication date

22 February 2017

1 reference

19 September 2017

1 reference

19 September 2017

35

1 reference

19 September 2017

35 Pt A

1 reference

19 September 2017

4457-4460

1 reference

Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.

19 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Group B streptococcal disease in infants: a case control study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Burden of invasive group B Streptococcus disease and early neurological sequelae in South African infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Epidemiology of Invasive Group B Streptococcal Disease in the United States, 1999-2005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Relationship between antenatal group B streptococcal vaginal colonization and premature labour

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Meta-analysis shows that infants who have suffered neonatal sepsis face an increased risk of mortality and severe complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Prevalence of maternal colonisation with group B streptococcus: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Chlorhexidine maternal-vaginal and neonate body wipes in sepsis and vertical transmission of pathogenic bacteria in South Africa: a randomised, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Maternal HIV infection and vertical transmission of pathogenic bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Risk factors and opportunities for prevention of early-onset neonatal sepsis: a multicenter case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Population-based incidence and etiology of community-acquired neonatal bacteremia in Mirzapur, Bangladesh: an observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Predictors of neonatal sepsis in developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Invasive Group B Streptococcal Disease in South Africa: Importance of Surveillance Methodology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Maternal colonization with Streptococcus agalactiae and associated stillbirth and neonatal disease in coastal Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Maternal group B Streptococcus-related stillbirth: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Stillbirths and intrauterine infection, histologic chorioamnionitis and microbiological findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Early-onset group B streptococcal disease in the United States: potential for further reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Review on the association of Group B Streptococcus capsular antibody and protection against invasive disease in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Correlates of protection of serotype-specific capsular antibody and invasive Group B Streptococcus disease in South African infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Bayesian inference on protective antibody levels using case-control data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Maternal antibody at delivery protects neonates from early onset group B streptococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

The Protective Value of Maternal Group B Streptococcus Antibodies: Quantitative and Functional Analysis of Naturally Acquired Responses to Capsular Polysaccharides and Pilus Proteins in European Maternal Sera

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Natural acquired humoral immunity against serotype-specific group B Streptococcus rectovaginal colonization acquisition in pregnant women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Serotype-Specific Cell-Mediated Immunity Associated With Clearance of Homotypic Group B Streptococcus Rectovaginal Colonization in Pregnant Women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Temporal Changes in Invasive Group B Streptococcus Serotypes: Implications for Vaccine Development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Serotype IV and invasive group B Streptococcus disease in neonates, Minnesota, USA, 2000-2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Association between low concentrations of antibodies to protein alpha and Rib and invasive neonatal group B streptococcal infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Alpha C protein-specific immunity in humans with group B streptococcal colonization and invasive disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Meningococcal surrogates of protection--serum bactericidal antibody activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Influenza immunology evaluation and correlates of protection: a focus on vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

Use of vaccines as probes to define disease burden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.02.025

10.1016/J.VACCINE.2017.02.025

7 January 2021

Identifiers

DOI

1 reference

release_cxz6z6ah7jagna5vqhe7kweg4i

19 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cxz6z6ah7jagna5vqhe7kweg4i

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

28237500

1 reference

PubMed ID

28237500